(redirected from hyperbilirubinemia)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
References in periodicals archive ?
When a patient presents with extreme hyperbilirubinemia (defined as >13 mg/dL) (3), a careful physical examination and appropriate laboratory and radiologic studies should be conducted (7, 9).
Prolonged neonatal unconjugated hyperbilirubinemia associated with breast feeding and a steroid, pregnane-3 (alpha), 20 (beta) diol in maternal milk that inhibits glucuronide formation in vitro.
Mild to moderate hyperbilirubinemia frequently occurs within the first postoperative week of liver transplantation.
represents a promising and new approach to the prevention of neonatal hyperbilirubinemia.
They address genetics, biochemistry, transport, metabolism of bilirubin, the physiology and epidemiology of neonatal hyperbilirubinemia, public policy measures, clinical management, and interventions for the prevention and treatment of hyperbilirubinemia and bilirubin encephalopathy in low and middle-income countries.
The risk of a composite outcome including death, adverse respiratory outcomes, hypoglycemia, treated hyperbilirubinemia, generalized seizures, necrotizing enterocolitis, hypoxic ischemic encephalopathy, periventricular leukomalacia, and suspected or proven sepsis was 6.
Q Our neonatologist is interested in screening for glucose-6-phosphate dehydrogenase (G6PD) for the evaluation of hyperbilirubinemia of newborns.
Because of myelosuppression, which was unexpected from chemotherapy, hyperbilirubinemia, hypertriglyceridemia, and hypofibrinogenemia, the patient was thought to have HPS.
Researchers at UCSF Children's Hospital and Kaiser Permanente's Division of Research in Oakland, CA, claim that their study is the firs to examine the effectiveness of universal screening for hyperbilirubinemia.
A recent increase nationwide in the number of infants with kernicterus has made prevention of severe hyperbilirubinemia a national priority.
The newly listed contraindicated regimens are a three-NRTI regimen with abacavir, tenofovir, and lamivudine (because of early virologic nonresponse); a three-NRTI regimen with didanosine, tenofovir, and lamivudine (because of a high rate of virologic failure); the combination of didanosine and stavudine (because of a high incidence of toxicities, including several deaths); the combination of atazanavir and indinavir (both of which can cause high-grade hyperbilirubinemia and jaundice); and emtricitabine plus lamivudine as a two-NRTI backbone (since both drugs have similar resistance profiles and minimal additive antiviral activity).